A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) Using an Administrative Healthcare Database in FranceFirst published 09/08/2024 Last updated 04/06/2025 EU PAS number: EUPAS1000000247StudyOngoing